We are pleased to announce that Dr. Monica Lopez returns this year to the Electronic Imaging International Symposium in Burlingame, CA as both a keynote speaker for the Autonomous Vehicles and Machines 2020 conference and course instructor.
The federal government has tapped a local company to help defend against superbugs.
Gaithersburg’s Adaptive Phage Therapeutics Inc. has earned a $10.2 million contract with the Department of Defense to help advance PhageBank, APT’s collection of viruses that target specific pathogens and kill drug-resistant bacteria. The ultimate goal is to make its therapy for drug-resistant infections available to the U.S. military and the public, APT said Wednesday.
Image: Dr. Carl Merril, third from right, with his son Greg, CEO and co-founder of Adaptive Phage Therapeutics, and other members of the team. ADAPTIVE PHAGE THERAPEUTICS INC.
China’s viral outbreak is straining the resources of front-line hospital staff in epidemic-stricken Wuhan, who have been forced to turn away patients because of a lack of beds and basic medical supplies.
Image: Chinese authorities are building a new hospital in the city of Wuhan following the outbreak of a virus that has infected more than 800 people and killed 26, aiming to complete it within six days. Photo: CCTV
About a month into the new gig, the former investment banker is nailing down her priorities for this year. On her list: Improving access to capital.
Image: Allyson Redpath is the Maryland Department of Commerce’s new director of entrepreneurship and small business. JOANNE S. LAWTON
The American Association for the Advancement of Science (AAAS) awarded its 2019 Newcomb Cleveland Prize to University of Maryland entomologists Raymond St. Leger, Brian Lovett and their seven West African collaborators.
The prestigious award is given to the authors of the most impactful paper published in AAAS’s flagship journal Science during the previous year.
Image: CREDIT: ETIENNE BILGO
The Precision Medicine World Conference (PMWC) is an independent and established conference series considered to be the preeminent precision medicine conference that attracts recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration. Since 2009, recognized as a vital cornerstone for all constituents of the health care and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.
Alexandria LaunchLabs™ in Maryland, will provide fully equipped, affordable laboratory/office space with flexible lease terms, supporting infrastructure, access to amenities, and supporting services and programming through the project’s consortium of world-class partners, including Alexandria Venture Investments, BioHealth Innovation, Montgomery County, and the City of Gaithersburg. This unique, startup environment will accelerate the growth of local early-stage life science companies.
Hilden, Germany, and Germantown, Maryland, January 9, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 2,500th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories worldwide, in Tübingen, Germany.
Cenata GmbH is a medically led genetic diagnostic laboratory offering prenatal testing, and repeat customer of the QIAsymphony, purchasing this milestone QIAsymphony SP as the third unit in their lab, expanding capabilities for circulating DNA purification and other applications.
Emmes today announced that the U.S. Food and Drug Administration (FDA) has approved a prescription-only medical device used to estimate the weight of infants who are up to 90 days of age.
The Mercy babyTAPE is a tape-measure-like device that permits health care professionals to estimate the body weight of preterm and full-term infants when a scale may not be available or practical to use. Accurately estimating pediatric patient weight is important for drug dosing, resuscitation interventions, and nutritional assessments. This easy-to-produce device could be especially useful in emergency or resource-constrained situations such as remote or rural areas, and in developing countries.
GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. The company has proposed conducting a safety and immunogenicity Phase 3 trial using Serum Neutralizing Antibodies (SNA) as an immune correlate of protection to predict clinical benefit of the vaccine candidate.
“Emergent is encouraged by the concurrence we have received from EMA in paving the path for chikungunya vaccine development based on SNA as the surrogate endpoint,” said Abbey Jenkins, senior vice president and vaccines business unit head at Emergent BioSolutions. “As a leading provider of travel health vaccines, Emergent seeks to address the threat posed by this highly debilitating virus by defining a realistic and optimal path to bring to market a much-needed chikungunya vaccine that could potentially serve patients worldwide. We look forward to continuing to work with regulators, including the U.S. Food and Drug Administration (FDA) with whom we had our End-of-Phase 2 meeting last December, as we plan to initiate a pivotal Phase 3 trial this year and define the approach for a post-approval confirmatory efficacy trial.”